FDA Inspection 1167109 — Rhode Island Blood Center, a Division of New York Blood Center, Inc., Westerly Donor Center

Rhode Island Blood Center, a Division of New York Blood Center, Inc., Westerly Donor Center — FEI 3010167719

The FDA completed an inspection of Rhode Island Blood Center, a Division of New York Blood Center, Inc., Westerly Donor Center on April 15, 2022 in Westerly, RI. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 2 citations were issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
April 15, 2022
Fiscal Year
2022
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Westerly, RI (United States)

Citations

IDCFRDescription
1809121 CFR 630.10(f)(6)(i)Physical Assessment Determination - Phlebotomy site
1809221 CFR 630.10(f)(6)(ii)Physical Assessment Determination - Skin Examination